|
1）Martin SJ, Henry CM, Cullen SP. A perspective on mammalian caspases as positive and negative regulators of inflammation. Mol Cell. 2012; 46: 387-97
|
|
|
|
2）Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009; 11: 615-28
|
|
|
|
|
|
3）Tang D, Kang R, Zeh HJ 3rd, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010; 1799: 131-40
|
|
|
|
|
|
4）Botturi K, Langelot M, Lair D, et al. Preventing asthma exacerbations: what are the targets? Pharmacol Ther. 2011; 131: 114-29
|
|
|
|
|
|
5）Aujla SJ, Alcorn JF. T(H)17 cells in asthma and inflammation. Biochim Biophys Acta. 2011; 1810: 1066-79
|
|
|
|
|
|
6）McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008; 181: 4089-97
|
|
|
|
|
|
7）Hou C, Zhao H, Liu L, et al. High mobility group protein B1 (HMGB1) in asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol Med. 2011; 17: 807-15
|
|
|
|
|
|
8）Shi Y, Sandoghchian Shotorbani S, Su Z, et al. Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis. Clin Dev Immunol. 2012; 2012: 295081
|
|
|
|
|
|
9）Shim EJ, Chun E, Lee HS, et al.The role of high-mobility group box-1 (HMGB1) in the pathogenesis of asthma. Clin Exp Allergy. 2012; 42: 958-65
|
|
|
|
|
|
10）Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res. 1999; 18: 629-67
|
|
|
|
|
|
11）Agresti A, Scaffidi P, Riva A, et al. GR and HMGB1 interact only within chromatin and influence each other’s residence time. Mol Cell. 2005; 18: 109-21
|
|
|
|
|
|
12）Dumitriu IE, Baruah P, Manfredi AA, et al. HMGB1: guiding immunity from within. Trends Immunol. 2005; 26: 381-7
|
|
|
|
|
|
13）Tang D, Kang R, Xiao W, et al. The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. J Immunol. 2007; 179: 1236-44
|
|
|
|
|
|
14）Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002; 3: 995-1001
|
|
|
|
|
|
15）Schierbeck H, Wähämaa H, Andersson U, et al. Immunomodulatory drugs regulate HMGB1 release from activated human monocytes. Mol Med. 2010; 16: 343-51
|
|
|
|
|
|
16）af Klint E, Grundtman C, Engström M, et al. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum. 2005; 52: 3880-9
|
|
|
|
|
|
17）Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012; 8: 195-202
|
|
|
|
|
|
18）Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med. 2011; 9: 216
|
|
|
|
|
|
19）Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009; 86: 1065-73
|
|
|
|
|
|
20）Sorci G, Riuzzi F, Giambanco I, et al. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta. 2013; 1833: 101-9
|
|
|
|
|
|
21）Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009; 11: 615-28
|
|
|
|
|
|
22）Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol. 2008; 20: 518-23
|
|
|
|
|
|
23）Ellerman JE, Brown CK, de Vera M, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007; 13: 2836-48
|
|
|
|
|